Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 19/20 | 0.65 |
| ▸ | CA2 | P00918 | 6/20 | 0.65 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12805162 | 0.93 | MAP2K1 (0.75) | MAP2K1CA2CA1 | |
| SCHEMBL1670511 | 0.85 | CA12 (0.56) | MAP2K1CA2CA1CA12CA7 | |
| SCHEMBL12002437 | 0.84 | MAP2K1 (0.82) | MAP2K1CA2CA1 | |
| SCHEMBL12710072 | 0.83 | MAP2K1 (0.62) | MAP2K1CA2CA1CA12CA7 | |
| SCHEMBL12710203 | 0.81 | MAP2K1 (0.54) | MAP2K1CA2CA1CA12CA7 | |
| SCHEMBL12709649 | 0.80 | MAP2K1 (0.56) | MAP2K1CA2CA1CA12CA7 | |
| SCHEMBL1672643 | 0.79 | MAP2K1 (0.76) | MAP2K1CA2CA1 | |
| SCHEMBL1669776 | 0.79 | MAP2K1 (1.00) | MAP2K1CA2CA1 | |
| SCHEMBL12801863 | 0.77 | CA12 (0.61) | MAP2K1CA2CA1CA12CA7 | |
| SCHEMBL12002442 | 0.73 | MAP2K1 (0.67) | MAP2K1CA2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120263714-A1 | SUBSTITUTED HALOPHENOXYBENZAMIDE DERIVATIVES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-10-18 | — | — | US | disclosed |
| US-20120263714-A1 | SUBSTITUTED HALOPHENOXYBENZAMIDE DERIVATIVES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-10-18 | — | — | US | disclosed |
| EP-2491014-A1 | SUBSTITUTED HALOPHENOXYBENZAMIDE DERIVATIVES | Bayer Pharma Aktiengesellschaft (DE) | 2012-08-29 | — | — | EP | disclosed |
| WO-2011047796-A1 | SUBSTITUTED HALOPHENOXYBENZAMIDE DERIVATIVES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-04-28 | — | — | WO | disclosed |
| WO-2011047796-A1 | SUBSTITUTED HALOPHENOXYBENZAMIDE DERIVATIVES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120263714-A1 | SUBSTITUTED HALOPHENOXYBENZAMIDE DERIVATIVES | RB1, HRH4, VEGFA | MAP2K1 2621/4885CA2 2031/4885CA1 4092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.